ClinicaliQ Trial Snapshot
- A Study of DB-1303/BNT323 vs Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) — Active Not Recruiting • Phase III • Oncology • NCT06018337.
- DB-1303/BNT323 versus standard chemotherapy for HER2-low, hormone receptor positive advanced breast cancer, measuring time to disease progression.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry [IHC]2+/in situ hybridization [ISH]- and IHC 1+) population. Conditions: Metastatic Breast Cancer Interventions: DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel Lead Sponsor: DualityBio Inc. Planned Enrollment: 541 participants